Introduction
============

The G-6-PD deficiency and haemoglobinopathies occur with high frequency in sub-Saharan Africa due to the malaria endemicity.[@b1-mjhid-8-1-e2016029] Indeed, the maintenance of these genetic abnormalities usually asymptomatic in the homozygous state, within populations, demonstrates the selective advantage that they confer in the heterozygous state to carriers against severe malaria.[@b2-mjhid-8-1-e2016029] S hemoglobin responsible for sickle cell disease is probably the most common serious of haemoglobinopathies in the world. Hemoglobin C is found only in parts of West Africa with the highest frequencies observed in Burkina Faso.[@b3-mjhid-8-1-e2016029] The beta S (β^s^) form of hemoglobin is caused by a single gene mutation: a "transversion" of the β~6~ globin gene (GAG to GTG) sixth codon of the first exon that result in the substitution of glutamic acid with valine (β~6~Glu → Val). As to the β^c^ form, it is induced by gene mutation "transition" of the β~6~ globin gene (GAG to AAG) sixth codon of the first exon that resulted in the substitution of glutamic acid for lysine (β~6~Glu→Lys). Since the Haldane hypothesis, several studies have demonstrated the protective effect of hemoglobin S and C against severe malaria although certain mechanisms remain controversial.[@b4-mjhid-8-1-e2016029]--[@b6-mjhid-8-1-e2016029]

The G-6-PD deficiency is the most common inherited enzymopathy, with over 400 million carriers worldwide.[@b7-mjhid-8-1-e2016029] It is a genetic X-linked abnormality with various clinical expressions in heterozygous female.[@b8-mjhid-8-1-e2016029] In humans, the G-6-PD gene is located in the telomeric region of the long arm of the X chromosome in position q28. It spans about 18 kb and contains 13 exons and 12 introns, ranging in size between 12 bp and 236 bp.[@b9-mjhid-8-1-e2016029]

The G-6-PD gene is highly polymorphic with over 180 mutations described and at least 35 mutant alleles with polymorphic frequencies. These polymorphisms are relatively common in different parts of the world.[@b10-mjhid-8-1-e2016029],[@b11-mjhid-8-1-e2016029] Over 85% of these mutations are single nucleotide substitutions. The enzyme deficiency is asymptomatic except in cases of infections, ingestion of certain foods or oxidizing molecules.[@b11-mjhid-8-1-e2016029] The severity of the disease depends on the genetic variant involved. G-6-PDB is the wild allele. The G-6-PDA, a non deficient variant, is the result of a substitution of adenine for guanine in position 376 of G-6-PD gene exon 5. It is faster than G6PDB electrophoretically and it does not cause haemolysis.

Most deficient variants G-6-PDA- are usually due to a second mutation on the G-6-PDA gene.[@b12-mjhid-8-1-e2016029] The most prevalent G-6-PDA- variant in sub-Saharan Africa and the most studied is the G-6-PDA-202A/376G. However, other variants like the G-6-PDA-376G/542T, 376G/680T, 376G/968C have been reported in some African populations, including West African populations with relatively high frequencies.[@b13-mjhid-8-1-e2016029]--[@b15-mjhid-8-1-e2016029] Also in their study in Mali, Maiga et *al.*[@b15-mjhid-8-1-e2016029] observed an association of other G-6-PD SNPs, including rs915942 and rs915941 with asymptomatic malaria in Dogon women. The allelic heterogeneity of the G-6-PD gene suggests the need to consider a broad range of G-6-PD variants in association studies. In this study we sought for six (06) single nucleotide polymorphisms substitution involved in the G-6-PD deficiency in patients with symptomatic malaria consulting in three health centers in the city of Ouagadougou in Burkina Faso.

Materials and Methods
=====================

Setting and type of study
-------------------------

This is a prospective study in which patients regardless of gender or ethnic group were recruited in three health centers in Ouagadougou, the capital of Burkina Faso, from September 27 to November 10, 2014. Malaria transmission is hyper-endemic and seasonal during the rainy season from June to October.

Study Population
----------------

The study involved 182 patients aged 1 to 72 years, attending Saint Camille Hospital of Ouagadougou (HOSCO), the Medical Center of Samandin and the Biomolecular Research Center Pietro ANNIGONI (CERBA) of Ouagadougou. Patients were sent to the laboratory when malaria was suspected, and underwent a Rapid Diagnostic Test using SD Bioline Malaria Ag Pf/Pan, after which positive individuals were included with their free and informed consent on condition that they are also positive microscopy.

Sampling
--------

The samples consisted of venous blood samples (5 ml of blood per subject adult and child by blood 3ml) in EDTA tubes. Part of the sample has been used for the realization of the Complete Blood Count (CBC), hemoglobin electrophoresis and thick blood. After that, the remainder of the sample was centrifuged at 15000 rpm for 5 minutes to separate the plasma from the pellet, aliquoted and stored at −80 ° C for molecular analysis.

Hematologic and thick smear
---------------------------

Hematological parameters were determined from blood samples with EDTA, using a blood counter ABX Micros 60 (ABX Diagnostics, Montpellier, France).

Hemoglobin Genotyping was made by electrophoresis in alkaline pH on a cellulose acetate tape. Tris-glycine at pH 9.5 was used as a buffer. The cells were washed and then lysed using 1% saponin. The migration was carried out for 60 minutes at 200 V on average.

The blades of thick films were stained for 10 minutes in a solution of 10% Giemsa. The reading was performed using an optical microscope objective 100 under oil immersion and parasite density positive slides was calculated and expressed as the number of parasites/μL. In preparing the final parasite density, trophozoites were counted simultaneously with 200 leukocytes. Two independent microscopists did quality control by a repeated examination of the blades. In the case of difference of more than 5% between the results of three readings, the average of the two closest results was then retained.

DNA extraction and genotyping of G-6-PD deficient variants
----------------------------------------------------------

Genomic DNA was extracted from blood pellet by the standard salting-out method.[@b11-mjhid-8-1-e2016029] The purity and the final concentration of DNA extracts were determined using the Biodrop μLITE (Isogen Life Science N.V./S.A, Temse, Belgium). All samples were initially genotyped by standard PCR. The amplification was done using the kit GENESPARK G6PD African (Immunospark, Rome, Italy) followed by electrophoresis on agarose gel 2% for six SNPs (G202A, A376G, A542T, G680T, T968C and C563T) involved in the G-6-PD deficiency.

PCR was performed in a reaction volume of 25 μL composed of 12.5 μL of Multiplex PCR smart mix (2x), 2 μL Primer Mixture (G6PD African), 8.5 μL of sterile water and 2 μL of 'DNA fragment (50--100 ng) of each sample. Electrophoresis was performed at 100 V for 1 hour.

Female individuals with mutations in position 202 and/or 376 were further analyzed by real-time PCR using TaqMan probes respectively (Applied Biosystems, Foster City, California, USA) include: rs1050829, rs1050828.[@b12-mjhid-8-1-e2016029]

Statistical Analyses
--------------------

Data were analyzed using the software Statistical Package for Social Sciences (SPSS) 21.0 (IBM, Armonk, NY, USA) and EpiInfo™ 7. Hardy-Weinberg equilibrium was determined in women according to the method described by Carter et *al*.[@b16-mjhid-8-1-e2016029] Pearson's chi-square test was used for categorical variables such as age groups, parasite density groups. ANOVA was employed in the comparison of hemoglobin and hematocrit means between groups. Non-parametric tests were used to compare the geometric mean of the parasite density. The difference was significant at p \<0.05.

Ethical Considerations
----------------------

The present study was approved by the Ethics Committee on Health Research of Burkina Faso (Deliberation No. 2014-9-128). Written informed consent was obtained from the adults and guardians of children.

Results
=======

Demographics and Clinical Characteristics
-----------------------------------------

Our study population consisted of 50.5% (92/182) of men and 49.5% (90/182) of women aged 1 to 72 years with a mean age of 17.1 ± 13.9 years. Children under 5 years old accounted for 19.2% (35/182) of the study population noted that while 46.7% (85/182) of individuals over 15 years. Socio-demographic analysis showed that 182 patients included in this study were derived from several different ethnic groups. Mossi represented the majority ethnic group with a proportion of 76.4% (139/182) of individuals whose parents were of this ethnic group ([Table 1](#t1-mjhid-8-1-e2016029){ref-type="table"}). Note that half of the group "Others" (10/20) was made up of ethnic groups from countries in the sub-region with a predominance of Nigerians (6/10). Over 43% of patients in our study had started treatment before the completion of the thick smear test. The study population was in following with Hardy-Weinberg equilibrium (p = 0.464).

Prevalence of deficiency G-6-PD and genotypes of hemoglobin
-----------------------------------------------------------

Conventional PCR analysis gave more than 64% (58/90) of females carrying mutations at position 202 and/or 376. Twenty-five of them were classified as homozygous and heterozygous by real-time PCR ([Figure 1](#f1-mjhid-8-1-e2016029){ref-type="fig"}). The G-6-PD deficiency genotyping showed a prevalence of 78.6% of individuals with a normal G-6-PD (29.7% genotype B, 13.2% of genotype A, 20.9% B/B, 12.1% B/A and 2.7% A/A) against 9.9% hemizygous/homozygous subjects (8.8% 202A/376G and 0.5% 376G/968C) ([Table 2](#t2-mjhid-8-1-e2016029){ref-type="table"}). Note that both parents of the individual carrier of G-6-PDA- (376G/968C) were Mossi while the parents of the female carrying the G-6-PDA- (376G/542T) variant were of the Gouro ethnic group of Ivory Coast.

She had the particularity of bearing G-6-PDA- (202A/376G) on one of the X chromosome and G-6-PDA- (376G/542T) on the other X chromosome with a parasite density of 40 parasites/μL. [Figure 2](#f2-mjhid-8-1-e2016029){ref-type="fig"} shows the bands of the different variants observed after electrophoresis.

Heterozygous females accounted for 11.5% (6.6% B/A- and 4.9% A/A-) of the study population. The prevalence of the hemizygous males was significantly higher than homozygous females (15.5% vs. 4.4% p = 0.015). The prevalence of hemoglobin genotypes was estimated to be 73.6%, 22.5% and 2.2% respectively for the genotypes AA, AC and AS. The allele frequency of HbS was 0.014 against 0.126 for HbC allele. The distribution of these genotypes was similar by sex and G-6-PD status ([Table 3](#t3-mjhid-8-1-e2016029){ref-type="table"}).

Correlation between polymorphisms of G-6-PD genes and HBB and symptomatic malaria
---------------------------------------------------------------------------------

The mean hemoglobin level in the study population was 11.7 g/dL ± 1.9. Approximately 66.0% (120/182) of patients had a hemoglobin level greater than 11g/dL. The majority (89.9% or 29/35) of children under the age of 5 had a hemoglobin below the level of 11 g/dL. However the distribution of hemoglobin and hematocrit was similar regardless of the G-6PD status and the hemoglobin genotype.

In the group of persons who have not started treatment prior to completion of thick smear, parasitaemia geometric mean was relatively lower in G-6PD hemizygous/homozygous individuals compared to non-deficient (3101.494 parasites/μL vs. 6879, 702 parasites/μL). Heterozygous females in this group had a similar parasite density than non-deficient individuals (7796.907 parasites/μL vs. 6879.702 parasites/μL). However, the correlation between the geometric mean of parasite density and G-6-PD status gave no statistically significant result ([Table 1](#t1-mjhid-8-1-e2016029){ref-type="table"}).

Among individuals carrying the S and/or C alleles(AS, AC, CC and SC) of hemoglobin were noted a mean parasite density of 2823.703 parasites/μL against 4454.813 parasites/μL for HbAA subjects with no statistically significant difference (p = 0.362).

Discussion
==========

G-6-PD has a considerable polymorphism with many genotypic variants known.[@b10-mjhid-8-1-e2016029] The Genotyping of six (06) SNPs involved in this genetic disease has allowed us to evaluate the frequency of different deficient variants in symptomatic malaria patients. The GENESPARK G6PD African Kit (Immunospark, Rome, Italy) through a conventional PCR followed by electrophoresis without enzymatic digestion is convenient and has the advantage of having an overview of six SNPs for each sample. However, the kit is limited when it comes to genotyping women because it indicates the presence of the mutation without allowing the distinction between homozygous and heterozygous. The prevalence of hemizygous/homozygous subjects was estimated at 9.9% in our study population. This prevalence is similar to those reported by the genotyping studies in Burkina Faso and the sub-region.[@b12-mjhid-8-1-e2016029],[@b16-mjhid-8-1-e2016029] With respect to gender, there was a significantly higher prevalence of hemizygous male (15.5%) than homozygous female (4.4%) since the disease is X-linked.[@b11-mjhid-8-1-e2016029] Among people with G-6-PD deficiency in this study, the G-6-PDA- (202A/376G) was the most common variant observed in 88.9% of deficiency cases. These observations are consistent with previous genotyping studies.[@b12-mjhid-8-1-e2016029],[@b16-mjhid-8-1-e2016029] The G-6-PD Betica Selma (376G/968C) was found in an individual of the Mossi ethnic group. This variant was observed in relatively high frequencies in the Gambian population,[@b14-mjhid-8-1-e2016029] and in this study it is identified for the first time in Burkina Faso. A study in Mali reported a high frequency of this variant in the Fulani (6.1%) compared to the Dogon (0.0%).[@b15-mjhid-8-1-e2016029]

A deficient woman of ethnic Gouro (Ivory Coast) in our study shows the A- variants (202A/376G) and Santamaria (376G/542T) on both X chromosomes with very low parasitaemia. All these observations suggest that these variants exist in our populations even if they occur with relatively low frequency in some areas. The highest frequencies of the G-6-PD Santamaria were reported in Sere population in Senegal.[@b13-mjhid-8-1-e2016029]

Our present results show that there is an underestimation of genotypes real prevalence causing the G-6-PD deficiency in Burkina Faso. The latter could explain the different frequencies of the deficit between genotyping studies and enzymatic quantification studies in our populations.[@b1-mjhid-8-1-e2016029],[@b17-mjhid-8-1-e2016029]

As part of this study, patients underwent a hemoglobin electrophoresis. A major sickle cell syndrome (SC) was demonstrated in 0.5% (1/182) of patients and 2.2% (4/182) had sickle cell trait AS. The most detected hemoglobin genotype was heterozygous AC present in 22.5% (41/182) of patients with 1.1% (2/182) of CC homozygosity. The prevalence of HbAC found in our study is comparable to that (19.1%) found by Simporeet*al*.[@b1-mjhid-8-1-e2016029] in 2007 and is higher than that found by Kafando et *al.*[@b18-mjhid-8-1-e2016029] in 2005 among newborns (15.4%). Prevalence of 14.7% and 13.0% of the AC hemoglobin were reported respectively by Amoako et *al*.[@b19-mjhid-8-1-e2016029] in Ghana and Travassos et *al*.[@b20-mjhid-8-1-e2016029] in Mali. All these studies show a higher rate of hemoglobin C in the sub-region. Indeed, West Africa is the epicenter of hemoglobin C.[@b3-mjhid-8-1-e2016029]

Although a reduced parasitaemia was observed in some cases (G-6-PD deficient vs.G-6-PD non-deficient individuals without treatment or HbAA subjects vs. HbS/HbC subjects), all analyses of the association between the G-6-PD status, hemoglobin genotypes, parasite density, and rate of hemoglobin or hematocrit gave no statistically significant differences. Our results are similar to those reported by Carter et *al*.[@b16-mjhid-8-1-e2016029] in 2011 in six African countries including Burkina Faso. The authors did not observe significant effects of G-6-PD genotypes on the hemoglobin and parasitaemia. The lack of correlation between haemoglobins and G-6-PD genotypes is expected, since respective genes are on different chromosomes; and it has been reported by a previous study.[@b21-mjhid-8-1-e2016029] The latter results also confirm that there is no protection against malaria infections. Indeed, the G-6-PD deficiency or haemoglobinopathies S and C did not offer protection against *Plasmodium falciparum* infections but may allow a favorable evolution of malaria.

The protection of the G-6-PD deficiency against severe form of malaria or malaria mortality is known, but the mechanism of protection is not entirely elucidated.[@b22-mjhid-8-1-e2016029]

In 2009 in a study in Gambia, Clark et *al*.[@b14-mjhid-8-1-e2016029] did not find an association between severe malaria and the 202A/376Gvariant only. However, pooling this variant with other deficiency alleles revealed the signal of protection. In 2014 in Mali, Maiga et *al*.[@b15-mjhid-8-1-e2016029] found no conclusive results on the protective effect of different G-6-PD genotypes correlated with uncomplicated malaria. The authors also suggest a higher risk of moderate malaria signs in Dogon 202A mutation carriers, especially in women. G-6-PD deficiency protective effects against cerebral malaria and an increased risk of severe malaria anemia have been reported in some studies investigating the correlation between this genetic disease and severe malaria.[@b23-mjhid-8-1-e2016029],[@b24-mjhid-8-1-e2016029] The allelic heterogeneity of the G-6-PD, phenotypic complexity and the difficulties of classification of clinical forms of malaria are all factors that can explain the differences between the different studies. The correlation between G-6-PD deficiency and protection against asymptomatic malaria has been reported in the literature.[@b12-mjhid-8-1-e2016029],[@b25-mjhid-8-1-e2016029] The selective advantage against malaria of G-6-PD heterozygous females has been early reported by Bienzle et *al*.[@b26-mjhid-8-1-e2016029] In a case-control study carried out in Tanzania, it was established through the number of G-6-PD SNPs, that only heterozygous women were protected against severe forms of malaria.[@b27-mjhid-8-1-e2016029] Another study in the Gambia had led to the same conclusion with variant G-6-PDA- (376G/968C).[@b28-mjhid-8-1-e2016029] In a case-control and cohort study in Kenya, Uyoga et *al.* showed, comparing boys and girls a significant protection from severe malaria among G6PD c.202T heterozygous girls but no evidence for protection among G6PD c.202T hemizygous boys and homozygous girls (OR 1·18, 0·99-1·40; p=0·056), thus the key to protection from severe malaria could be the girls heterozygous for G6PD deficiency.[@b29-mjhid-8-1-e2016029]

Our study population size was limited in deepening the analysis. Parameters such as treatment before completion of thick smears are factors that may influence parasite density and bias the association analyses.

In 2015 in Nigeria Igbeneghu et *al*.[@b30-mjhid-8-1-e2016029] reported a strong protection of HbAS and HbAC genotypes against asymptomatic *Plasmodium falciparum*. Protection of HbAC carriers against clinical forms of *Plasmodium falciparum* malaria has also been reported in Mali.[@b20-mjhid-8-1-e2016029]

During the same year, Mangano et *al*.[@b5-mjhid-8-1-e2016029] reported in Burkina Faso that HbAS genotype was associated with a 70% reduction of parasite *Plasmodium falciparum* unlike HbAC carriers, although a strong protection was also observed in HbCC and HbSC subjects. Our results suggest that even if haemoglobinopathies S or C protect against severe forms of malaria like G-6-PD deficiency, they do not confer protection against *Plasmodium falciparum* infections.

Conclusion
==========

Our study confirms that the G-6-PDA- variant (202A/376G), the most common in Burkina Faso, does not confer protection against *Plasmodium falciparum* malaria infections. However, it shows that other variants such as T968C and probably A542T exist in our population. Further investigations are required in a larger population with well certain ethnic groups for a real estimate of the prevalence of Glucose-6-phosphate dehydrogenase variants involved in a possible association with the resistance to various kinds of malaria.
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###### 

Socio-demographic and clinical Characteristics according to G-6-PD status

  Characteristics                                                        Hemizygous & homozygous (N = 18)   Heterezygous (N = 21)        Normal (N = 143)              Total (N = 182)               p
  ---------------------------------------------------------------------- ---------------------------------- ---------------------------- ----------------------------- ----------------------------- -------
  **Age (years)**                                                                                                                                                                                    
  \< **5, n (%)**                                                        4 (22.2)                           0 (0.0)                      31 (21.7)                     35 (19.2)                     
  **5 à 15, n (%)**                                                      4 (22.2)                           6 (28.6)                     52 (36.3)                     62 (34.1)                     0.051
  \> **15, n (%)**                                                       10 (55.6)                          15 (71.4)                    60 (42.0)                     85 (46.7)                     
  **Mean, \[interval\]**                                                 17.1 \[1 -- 34\]                   26.8 \[7 -- 60\]             15,6 \[1 -- 72\]              17.1 \[1 -- 72\]              0.002
  **Parasitaemia (parasites/μL)**                                                                                                                                                                    
  \< **1 000, n (%)**                                                    4 (22.2)                           5 (23.8)                     40 (28.0)                     49 (26.9)                     
  **1 000 -- 10 000, n (%)**                                             6 (33.3)                           5 (23.8)                     40 (28.0)                     51 (28.0)                     0.927
  \> **10 000, n (%)**                                                   8 (44.4)                           11 (52.4)                    63 (44.0)                     82 (45.1)                     
  **geometric mean μL-1 \[interval\]**                                   4235.470 \[100 -- 81300,0\]        3750.758 \[40 -- 96000,0\]   3945.445 \[40 -- 177778,0\]   3950.090 \[40 -- 177778,0\]   0.763
  **Hemoglobin, mean g.dL-1**                                            11.8961                            11.9586                      11.6349                       11.6981                       0.704
  **Hematocrit, mean %**                                                 37.0913                            38.1373                      35.1266                       35.6529                       0.368
  **Hemoglobin genotypes**                                                                                                                                                                           
  **HbAA, parasites mean/μL**                                            6541.271                           4511.546                     4748.802                      4454.813                      
  **HbS/C, parasites mean/μL Treatment**                                 2211.760                           1238.458                     2320.111                      2823.703                      0.362
  **No, n (%)\[Parasitaemia mean/μL\]**                                  13 (72.2) \[9522.729\]             12 (57.1) \[7796.907\]       78 (54.5) \[6879.702\]        103 (56.6) \[6312.948\]       0.357
  **Yes, n (%)\[Parasitaemia mean/μL\]**                                 5 (27.8) \[3101.494\]              9 (42.9) \[1413.779\]        65 (45.5) \[2024.546\]        79 (42.9) \[2143.487\]        0.500
  **Ethnic groups**[\*](#tfn1-mjhid-8-1-e2016029){ref-type="table-fn"}                                                                                                                               
  **Mossi n (%)**                                                        13 (72.2)                          14 (66.7)                    112 (78.3)                    139 (76.4)                    
  **Mix n (%)**                                                          4 (22.2%)                          2 (9.5%)                     17 (11.9%)                    23 (12.6)                     0.221
  **Others n (%)**                                                       1 (5.6)                            5 (23.8%)                    14 (9.8)                      20 (11.0)                     

**Mossi**= individuals whose two parents are Mossi, **Mix** = One of the parent is Mossi, **Others** = None of the parent is Mossi.

###### 

G-6-PD deficiency and its variants prevalence according to sex

  G-6-PD Status       Males, n (%)    Females, n (%)   Total, N (%)
  ------------------- --------------- ---------------- ---------------
  Normal              78 (84.8)       65 (72.2)        143 (78.6)
  Heterozygous        0 (0.0)         21 (23.3)        21 (**11.5)**
  Hemi & homozygous   14 (**15.2)**   4 (**4.4)**      18 (**9.9)**
  Total               92 (100.0)      90 (100.0)       182 (100.0)
  Variants A-                                          
  202A/376G           13 (92.9)       3 (75.0)         16 (88.9)
  202A/968C           1 (7.1)         0 (0.0)          1 (5.5)
  202A/376G/542T      0 (0.0)         1 (0.25)         1 (5.5)
  Total               14 (100.0)      4 (100.0)        18 (100.0)

###### 

Study population characteristics according to HBB genotypes and HbS, HbC allele frequencies

                               Individuals in functions of their hemoglobin genotypes   Frequency                             
  ---------------------------- -------------------------------------------------------- ----------- --- --- --- ----- ------- ---------
  **Sex**                                                                                                                     
  **Male**                     68                                                       20          3   1   0   92    0.016   0\. 120
  **Female**                   66                                                       21          1   1   1   90    0.011   0.133
  **G-6-PD Status**                                                                                                           
   **Normal**                  106                                                      32          3   1   1   143   0.014   0.122
   **Heterozygous**            18                                                       3           0   0   0   21    0.000   0.071
   **Hemi** & **homozygous**   10                                                       6           1   1   0   18    0.028   0.222
  **Age Groups**                                                                                                              
   **\< 5 years**              25                                                       9           1   0   0   35    0.014   0.129
   **5 -- 15 years**           47                                                       10          3   2   0   62    0.024   0.113
   **\> 15 years**             62                                                       22          0   0   1   85    0.006   0.135
  **Total**                    134                                                      41          4   2   1   182   0.014   0.126
